Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Nicotinamide N-Methyl Transferase and Cancer-Associated Thrombosis: Insights to Prevention and Management Publisher Pubmed



Jabbari P1 ; Ardakany MR2 ; Ebrahimi S3 ; Rezaei N4, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Molecular, Cell & Systems Biology, University of California, Riverside, 92521, CA, United States
  2. 2. Department of Dermatology, Imam Khomeini Hospital, Jondishapour University of Medical Science, Ahvaz, Iran
  3. 3. Research Department of Rajaei Heart Center, Iran University of Medical Sciences, Tehran, Iran
  4. 4. Research Center for Immunodeficiency, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Epigenomics Published:2023


Abstract

Nicotinamide metabolism is important in carcinogenesis. Nicotinamide affects the cellular methyl pool, thus affecting DNA and histone methylation and gene expression. Cancer cells have increased expression of nicotinamide N-methyl transferase (NNMT), the key enzyme in nicotinamide metabolism. NNMT contributes to tumor angiogenesis. Overexpression of NNMT is associated with poorer prognosis in cancers. Additionally, NNMT can contribute to cancer-associated morbidities, such as cancer-associated thrombosis. 1-methylnicotinamide (1-MNA), a metabolite of nicotinamide, has anti-inflammatory and antithrombotic effects. Therefore, targeting NNMT can affect both carcinogenesis and cancer-associated morbidities. Several antitumor drugs have been shown to inhibit NNMT expression in cancer cells. Implementing these drugs to reverse NNMT effects in addition to 1-MNA supplementation has the potential to prevent cancer-associated thrombosis through various mechanisms. © 2023 Future Medicine Ltd.